CD274 and neoplasm: PD-1/PD-L1 inhibitors belong to immune checkpoint blocking drugs (1); they can block the binding of tumor cells to PD-1 of T cells by means of PD-L1, restore the ability to recognize tumor cells, and further restore the cell recognition and killing ability of T cells (1).